Skip to Main Content

++

KAPOSI SARCOMA (KS)

++

Epidemiology of KS

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print
Epidemiology of KS
Incidence/100,000
United States
Males: 2.1
Females: 0.11
Africa
Males: 39.3
Females: 21.8

Stage at Presentation in HAART Era (Based on ACTG Modified TIS Staging)

Poor risk: 25%
Good risk: 75%

ACTG: AIDS Clinical Trials Group

Deaths caused by AIDS since advent of HAART have decreased by more than 50%

 

Nasti G et al. J Clin Oncol 2003;21:2876–2882

++

Pathology

  1. All KS is caused by human herpesvirus 8 (HHV-8), also called the Kaposi sarcoma-associated herpesvirus (KSHV), a gamma herpesvirus first identified in 1994

  2. Pathology shows a highly vascular tumor with spindle-shaped cells staining positive for KSHV

 

Moore PS, Chang Y. N Engl J Med 1995;332:1181–1185

++

Work-up

  1. Biopsy to confirm diagnosis

  2. HIV serology

  3. CD4 and HIV-1 viral load

  4. Assessment of tumor extent:

    • Physical examination of the skin and lymph nodes

    • Chest x-ray

    • Chest CT scan not routinely indicated unless x-ray is abnormal

    • For GI symptoms, work-up as indicated

    • Fecal occult blood testing

 

Di Lorenzo G et al. Lancet Oncol 2007;8:167–176

++

Staging (Validated ACTG TIS Staging for AIDS-KS)

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print
Staging (Validated ACTG TIS Staging for AIDS-KS)
Good Risk: Stage 0 (Stage 0: All criteria below must be satisfied) Poor Risk: Stage 1 (Stage 1: If any of the criteria are present)
Tumor (T)
Confined to skin and/or lymph nodes

Tumor-associated edema or ulceration

Extensive oral KS

Gastrointestinal KS

KS in other nonnodal viscera

Immune System (I)
CD4 cells >150/mm3 CD4 cells <150/mm3
Systemic Illness (S)
  • No history of opportunistic infection or thrush

  • No B symptoms persisting >2 weeks, including

    1. Unexplained fever

    2. Night sweats

    3. >10% involuntary weight loss

    4. Diarrhea

  • Performance status >70 (Karnofsky scale)

  • History of opportunistic infections, thrush, or both

  • B symptoms present

     

     

     

     

  • Performance status <70 (Karnofsky scale)

  • Other HIV-related illness (eg, neurologic disease, lymphoma)

Staging example:

A patient with KS restricted to the skin, CD4 count of 10 cells/mm3, and a history of Pneumocystis jirovecii (formerly, P. carinii) pneumonia would be T0 I1 S1

According to the AIDS Clinical Trials Group (ACTG). Staging takes into account tumor extent (T), immune status (I), and systemic illness (S)

 

Notes:

  1. In the HAART era, immune status may not be prognostically predictive. However, in patients with resistant HIV, immune status may be relevant

  2. In the HAART era, poor prognosis is T1S1. All other stages are considered good prognosis

 

Krown SE et al. J Clin Oncol 1997;15:3085–3092

Nasti G et al. J Clin Oncol 2003;21:2876–2882

++

Expert Opinion

++

Kaposi sarcoma, as an AIDS-presenting manifestation in antiretroviral therapy (ART) naïve patients, often responds to ART. However, not all patients achieve lesion resolution with ART. In addition to ART, radiotherapy or surgery can be used to ...

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.